|
|
4380 North Campbell Avenue, Suite 205
Tucson, AZ 85718 USA
phone:520.529.1000
fax:520.529.3001
|
|
| Symbol |
private |
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.amplimed.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Novel drugs for the treatment of cancer. |
|
| Management |
| Dr. Ron Garren, President; Dr. Evan Hersh, Executive VP, and Chief Medical Officer; Dr. David Alberts, VP, Industrial Liaison; Dr. Robert T. Dorr, VP, Chief Operating Officer/Scientific Officer; Dr. William Remers, VP, Chemistry/Manufacturing/CMC; Steve Steinman, VP, Regulatory; Robert Baker, VP, Manufacturing |
| |
|
|
| |
|
| Keywords |
| cancer research, pancreatic cancer, malignant melanoma, lung cancer, multiple myeloma |
|
|
|
| Description |
|
AmpliMed Corporation develops novel drugs for the treatment of cancer. Their lead product, Amplimexon which has shown particular promise for the treatment of pancreatic cancer, malignant melanoma, lung cancer and multiple myeloma. |
|
| Products / Services |
Amplizone, Amplimexon. Other products in their portfolio have promise in ovarian, breast, prostate and other common cancers
|
|
| Technology / Differentiation |
| The Company's compounds have novel ways of killing cancer cells which are distinct from many other anticancer drugs. They may also avoid some of the toxicity which is common in cancer drugs, and bypass the resistance mechanisms built up by the cancer cells. |
|
| Market / Customers |
Physicians and cancer patients.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members